Use your specific donor whether it be HLA matching or engineered cells for immuno-oncology studies using CD34+ humanized NSG™ mice.
NSG™ mice engrafted with CD34+ hematopoietic stem/progenitor cells (HSPCs) are an attractive model for immune-oncology efficacy studies, as they are a validated platform that provides bone marrow engraftment with development of multi-lineage human immune cells in the peripheral blood. However, the CD34+ donors are typically selected by the mouse provider rather than by the customer. For many studies, such as those with engineered cells (e.g. HSPCs and CAR-T), it may be preferential that the study sponsor dictates the donor for CD34+ humanization in NSG mice. Hera has demonstrated through effective recipient conditioning, transplantation and flow cytometric (FC) analysis efficient engraftment of engineered CD34+ HSPCs as indicated by high levels of human CD45+ chimerism in the blood and bone marrow.
Request A Proposal
Download Publications

CD34+ humanized IO Services

  • Humanization via peripheral blood or bone marrow-derived cells
  • For new donors Hera suggests a pilot engraftment study be conducted
  • Immuno-oncology efficacy studies

FC analysis of peripheral blood for human CD45+ at 8 weeks.

Blood collected at 8 weeks post-transplant of G-CSF mobilized peripheral blood CD34+ cells was subjected to FC analysis for human and mouse CD45. Left panel: group 1 (vehicle control); center two panels: group 2; right two panels: group 3.

FC analysis of bone marrow for human CD45+ at 8 weeks.

Bone marrow collected at 8 weeks post-transplant of G-CSF mobilized peripheral blood CD34+ cells was subjected to FC analysis for human and mouse CD45. Left panel: group 1 (vehicle control); center two panels: group 2; right two panels: group 3.